Comparison of Safety and Efficacy of de Novo Everolimus
Status:
Completed
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
Nowadays, de novo everolimus regimen in renal transplant patients is considered for reduction
of cyclosporine dose and it is mentioned that this regimen not only has similar safety and
efficacy, but also could prevent Cytomegalovirus (CMV )infections. So, the aim of this study
was comparison of safety and efficacy of de novo everolimus plus low dose of cyclosporine
with standard dose of cyclosporine plus cellcept on CMV virus infections prevention in renal
transplant patients.